APA (7th ed.) Citation

Muntañola, A., Arguiñano‐Pérez, J. M., Dávila, J., de Villambrosia, S. G., Carpio, C., Jiménez‐Ubieto, A., & Salar, A. (2023). Safety and tolerability of a 90‐minute rapid infusion of Sandoz biosimilar rituximab in B‐cell lymphoproliferative disorders in a real‐world setting. CTS: Clinical & Translational Science, 16(2), 305. https://doi.org/10.1111/cts.13450

Chicago Style (17th ed.) Citation

Muntañola, Ana, José María Arguiñano‐Pérez, Julio Dávila, Sonia González de Villambrosia, Cecilia Carpio, Ana Jiménez‐Ubieto, and Antonio Salar. "Safety and Tolerability of a 90‐minute Rapid Infusion of Sandoz Biosimilar Rituximab in B‐cell Lymphoproliferative Disorders in a Real‐world Setting." CTS: Clinical & Translational Science 16, no. 2 (2023): 305. https://doi.org/10.1111/cts.13450.

MLA (9th ed.) Citation

Muntañola, Ana, et al. "Safety and Tolerability of a 90‐minute Rapid Infusion of Sandoz Biosimilar Rituximab in B‐cell Lymphoproliferative Disorders in a Real‐world Setting." CTS: Clinical & Translational Science, vol. 16, no. 2, 2023, p. 305, https://doi.org/10.1111/cts.13450.